The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | Current and emerging unmet needs in R/R multiple myeloma: improving QoL & novel therapeutic options
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses unmet needs in relapsed/refractory (R/R) multiple myeloma, emphasizing the poor quality of life (QoL) experienced by patients. Dr Ramasamy also highlights the need to develop novel agents that not only improve QoL, but also provide a valuable therapeutic benefit. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
